TY - JOUR
T1 - Spontaneous partial recovery of striatal dopaminergic uptake despite nigral cell loss in asymptomatic MPTP-lesioned female minipigs
AU - Lillethorup, Thea Pinholt
AU - Noer, Ove
AU - Alstrup, Aage Kristian Olsen
AU - Cristiano Real Gregório, Caroline
AU - Stokholm, Kathrine
AU - Thomsen, Majken
AU - Zaer, Hamed
AU - Orlowski, Dariusz
AU - Mikkelsen, Trine Werenberg
AU - Glud, AN
AU - Nielsen, Erik Holm Toustrup
AU - Schacht, Anna Christina
AU - Winterdahl, Michael
AU - Brooks, David J
AU - Sørensen, Jens Christian Hedemann
AU - Landau, Anne
PY - 2022/7
Y1 - 2022/7
N2 - The Göttingen minipig is a large animal with a gyrencephalic brain that expresses –complex behavior, making it an attractive model for Parkinson's disease research. Here, we investigate the temporal evolution of presynaptic dopaminergic function for 14 months after injections of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the minipig using a multi-tracer longitudinal positron emission tomography (PET) design. We injected seven sedated minipigs with 1–2 mg/kg of MPTP, and two with saline, three times a week over four weeks. We monitored behavioral deficits using a validated motor scale and walking mat. Brains were imaged with (+)-⍺-[11C]-dihydrotetrabenazine ([11C]-DTBZ) and [18F]-dihydroxyphenylalanine ([18F]-FDOPA) PET at baseline and 1, 3, 10 and 14 months after MPTP injection, and immunohistochemistry was used to assess nigral cell loss. The minipigs showed mild bradykinesia and impaired coordination at early timepoints after MPTP. PET revealed decreases of striatal [11C]-DTBZ and [18F]-FDOPA uptake post-MPTP with partial spontaneous recovery of [18F]-FDOPA after 10 months. Postmortem analysis estimated an MPTP-induced nigral loss of 57% tyrosine hydroxylase+ and 43% Nissl-stained cells. Normal motor function despite substantial damage to the dopaminergic system is consistent with prodromal Parkinson's disease, and offers an opportunity for testing disease-modifying therapies. However, partial spontaneous recovery of dopamine terminal function must be taken into account in future studies.
AB - The Göttingen minipig is a large animal with a gyrencephalic brain that expresses –complex behavior, making it an attractive model for Parkinson's disease research. Here, we investigate the temporal evolution of presynaptic dopaminergic function for 14 months after injections of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the minipig using a multi-tracer longitudinal positron emission tomography (PET) design. We injected seven sedated minipigs with 1–2 mg/kg of MPTP, and two with saline, three times a week over four weeks. We monitored behavioral deficits using a validated motor scale and walking mat. Brains were imaged with (+)-⍺-[11C]-dihydrotetrabenazine ([11C]-DTBZ) and [18F]-dihydroxyphenylalanine ([18F]-FDOPA) PET at baseline and 1, 3, 10 and 14 months after MPTP injection, and immunohistochemistry was used to assess nigral cell loss. The minipigs showed mild bradykinesia and impaired coordination at early timepoints after MPTP. PET revealed decreases of striatal [11C]-DTBZ and [18F]-FDOPA uptake post-MPTP with partial spontaneous recovery of [18F]-FDOPA after 10 months. Postmortem analysis estimated an MPTP-induced nigral loss of 57% tyrosine hydroxylase+ and 43% Nissl-stained cells. Normal motor function despite substantial damage to the dopaminergic system is consistent with prodromal Parkinson's disease, and offers an opportunity for testing disease-modifying therapies. However, partial spontaneous recovery of dopamine terminal function must be taken into account in future studies.
KW - BINDING
KW - Dopamine
KW - EXPRESSION
KW - GOTTINGEN MINIPIG
KW - MPTP
KW - Minipig
KW - PARKINSONS-DISEASE
KW - PARS COMPACTA
KW - PET
KW - PRIMATE MODEL
KW - Parkinson?s disease
KW - Positron emission tomography
KW - SUBSTANTIA-NIGRA
KW - TREATED MONKEYS
KW - TYROSINE-HYDROXYLASE
KW - Vesicular monoamine transporter 2
UR - http://www.scopus.com/inward/record.url?scp=85133918522&partnerID=8YFLogxK
U2 - 10.1016/j.neuro.2022.05.006
DO - 10.1016/j.neuro.2022.05.006
M3 - Journal article
C2 - 35569565
SN - 0161-813X
VL - 91
SP - 166
EP - 176
JO - NeuroToxicology
JF - NeuroToxicology
ER -